Alzheimer Disease

Nymox protein biomarker for Alzheimer is years ahead of competition

Published in Health Business Week, January 12th, 2007

Nymox Pharmaceutical Corporation's (NYMX) AlzheimAlert test is years ahead of the competition, according to Brian Doyle, Nymox's senior manager for Worldwide Sales and Marketing.

The urine-based test, which measures levels of a protein-based biomarker for Alzheimer disease, is available to physicians in major markets, including Europe and the United States. A recent article in The Wall Street Journal described competing tests in this area that employ measuring multiple protein biomarkers and quoted a conservative estimate that these possible competitors were three to five years away from the clinic.

"Experience has shown that tests which require...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week

Source: Health Business Week (2007-01-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry